UroMems Raises Record $47 million (€44 Million) in Series C Financing to Fund Pivotal Clinical Trials of the UroActive™ System, the First Smart Automated Implant to Treat Stress Urinary Incontinence

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

UroMems-ClinicalTrial

More Like This

PR Newswire associated0

UroMems Reaches Significant Milestone: Successful Results in Clinical Feasibility Study of UroActive™ Smart Implant for Stress Urinary Incontinence Treatment

PR Newswire associated0

UroMems Announces Results of First-Ever Smart Artificial Urinary Sphincter Implant in Female Patient to Treat Stress Urinary Incontinence

PR Newswire associated0

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

PR Newswire associated0

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Business Wire logo

MMI Raises $110 Million in Series C Financing

PR Newswire associated0

Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome

Business Wire logo

Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors

The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement